Arcellx, Inc. (ACLX)
$
113.79
-0.09 (-0.08%)
Key metrics
Financial statements
Free cash flow per share
-3.7756
Market cap
6.6 Billion
Price to sales ratio
0
Debt to equity
0
Current ratio
0
Income quality
0.9184
Average inventory
0
ROE
-0.7326
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Arcellx, Inc., a clinical-stage biotechnology company, is focused on developing innovative immunotherapies for patients battling cancer and other serious illnesses. The company reported an income before tax of -$228,865,000.00 showcasing its pre-tax profitability, which reflects its effective business strategies and investment in advanced therapies. Additionally, the company reported depreciation and amortization expenses of $0.00 indicating the wear and tear of its assets as it scales its development efforts. To support its operations, Arcellx reported selling, general, and administrative expenses of $117,758,000.00 which highlight its operational overhead costs associated with running a clinical-stage organization. The net total of other income and expenses is $24,218,000.00 reflecting non-core financial activities that influence the overall financial health of the company. The operating income ratio is 0.00 indicating the company's operational profitability margin, further solidifying its position in the competitive biotechnology landscape. As Arcellx continues its clinical trials and advances its product candidates, including CART-ddBCMA for relapsed or refractory multiple myeloma, it demonstrates its commitment to addressing unmet medical needs. In the financial market, the stock is reasonably priced at $77.86 appealing to a broad range of investors who seek opportunities in the biotechnology field. The stock has an average trading volume of 2,174,675.00 indicating moderate liquidity that reflects investor interest and active market participation. With a mid-range market capitalization of $6,579,664,491.00 the company is a steady performer, ranked among notable players in the clinical-stage biotechnology industry. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape through its pioneering therapies and research initiatives. Furthermore, it belongs to the Healthcare sector, driving innovation and growth as it works towards providing solutions for challenging health issues and enhancing the quality of life for patients.
Is Arcellx, Inc. (ACLX) a good investment?
Investing in Arcellx, Inc. (ACLX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Arcellx, Inc. (ACLX)'s stock forecast?
Analysts predict Arcellx, Inc. stock to fluctuate between $47.86 (low) and $114.26 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Arcellx, Inc.'s market capitalization?
As of 2026-02-27, Arcellx, Inc.'s market cap is $6,579,664,491, based on 57,822,871 outstanding shares.
How does Arcellx, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Arcellx, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Arcellx, Inc. (ACLX) stock?
To buy Arcellx, Inc. (ACLX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACLX. Place an order (Market, Limit, etc.).
What is the best time to invest in Arcellx, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Arcellx, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$4.07 | Growth: 103.50%.
Where can I find Arcellx, Inc.'s investor relations reports?
Visit https://arcellx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Arcellx, Inc.?
You can explore historical data from here
What is the all-time high and low for Arcellx, Inc. stock?
All-time high: $114.26 (2026-02-23) | All-time low: $6.04 (2022-05-17).
What are the key trends affecting Arcellx, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Arcellx, Inc. (NasdaqGS: ACLX) to Gilead Sciences, Inc. (NasdaqGS: GILD). Under the terms of the proposed transaction, shareholders of Arcellx will receive $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones. KSF is seeking to deter.
prnewswire.com
NEW YORK, Feb. 23, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Arcellx, Inc. (NASDAQ: ACLX ) related to its sale to Gilead Sciences, Inc. Under the terms of the proposed transaction, Arcellx shareholders are expected to receive $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones.
investopedia.com
Shares of a biotech firm are jumping on a down day for stocks.
prnewswire.com
MILWAUKEE, Feb. 23, 2026 /PRNewswire/ -- Ademi LLP is investigating Arcellx (NASDAQ: ACLX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Gilead. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
invezz.com
Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a $7.8 billion all-cash deal. The stock's move wasn't a mystery rally.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Arcellx, Inc. (NASDAQ: ACLX) to Gilead Sciences, Inc. for $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones. Halper Sadeh encourages Arcellx shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or zhalper@ha.
wsj.com
Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.
reuters.com
Gilead Sciences said on Monday it will buy cancer therapy developer Arcellx for an implied equity value of $7.8 billion, sending shares of Arcellx climbing 77.8% to $113.99 in premarket trading.
businesswire.com
FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #ACLX--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incura.
fool.com
Perceptive Advisors sold 1,002,282 Arcellx shares in the fourth quarter; the estimated trade size was $79.96 million based on quarterly average pricing. Meanwhile, the quarter-end value of the Arcellx position decreased by $107.06 million, reflecting both share sales and price changes.
See all news
